Response rates with zilucoplan among patients with generalized myasthenia gravis in an interim analysis of RAISE-XT, a Phase 3 open-label extension study

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

Study Limitations: RAISE-XT was designed to evaluate safety and was not placebo controlled, therefore efficacy or clinical significance should be interpreted with caution.